Across the cagrilintide clinical program, the dominant tolerability issues have been gastrointestinal: nausea, reduced appetite, constipation, and, less commonly, vomiting a profile shared with pramlintide and with GLP-1 agonists, and mechanistically expected from a compound that slows the stomach and engages the area postrema
The bottom line: Coverage varies a lot from plan to plan, so people should be prepared for a similar process to what theyve seen with injectables, at least until insurance companies update their policies
The dogs were raised in an open feeding farm under conditions involving natural light
A well-rounded approach includes monitoring body composition, metabolic health, daily symptoms, and overall quality of life
Sin stock en tiendaUsaqucn, Bogota D.c
Diabetes Obes Metab 13(5):426433